Pintex Pharmaceuticals
A private pharmaceuticals company headquartered in Watertown, MA.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
Related Content
Pintex Pharmaceuticals Inc. operated as a biopharmaceutical firm focused on the development of novel therapeutics and diagnostics for cancer treatment. Founded in 1999 and based in Watertown, Massachusetts, the company built its research and development efforts on foundational technology licensed from the Salk Institute for Biological Studies and Harvard University. The core of its scientific approach was centered on inhibiting the Pin1 enzyme, which plays a role in the development of various cancers, with a key patent for the "Use of pin1 inhibitors for treatment of cancer."
The company's business model was typical of a venture-backed drug discovery enterprise, securing capital to fund long-term research and clinical development with the goal of bringing a new drug to market or being acquired. Pintex successfully raised a total of $11.7 million through multiple funding rounds, including a Series A in 2000 that raised $3 million and subsequent rounds in 2002 and 2003. Its investor base included venture capital firms such as BioVentures Investors, Canaan Partners, and Zero Stage Capital.
Throughout its operation, Pintex engaged in strategic partnerships, including a notable deal with the Max Planck Society in 2003 to advance its research programs. The company's trajectory culminated on April 1, 2005, when it was acquired by Vernalis, a UK-based biotechnology company. At the time of the acquisition, Pintex was in the product development stage, demonstrating progress in its mission to translate its scientific discoveries into viable cancer therapies. Following the acquisition, the company ceased to operate as an independent entity.
Keywords: Pintex Pharmaceuticals, cancer therapeutics, cancer diagnostics, Pin1 inhibitors, Salk Institute, drug discovery, oncology, biopharmaceutical, Vernalis acquisition, venture-backed pharma, Watertown biotech, Harvard University technology, Max Planck Society collaboration, BioVentures Investors, Canaan Partners, Zero Stage Capital, pharmaceutical development, preclinical research